Inhibitors of angiogenesis in a clinical perspective

Anticancer Drugs. 1996 Sep;7(7):723-7. doi: 10.1097/00001813-199609000-00001.

Abstract

Inhibition of angiogenesis or preventing the outgrowth of new blood vessels towards a tumor is one of the most promising areas of anticancer drug development. Several angiogenesis inhibitors are now on the verge of being tested in clinical trials. This review discusses possible applications of inhibitors of angiogenesis and whether the current methodologies for testing novel anticancer drugs are appropriate to evaluate the efficacy of inhibitors of angiogenesis.

Publication types

  • Review

MeSH terms

  • Angiostatins
  • Cyclohexanes
  • Endothelial Growth Factors / antagonists & inhibitors
  • Humans
  • Integrins / antagonists & inhibitors
  • Lymphokines / antagonists & inhibitors
  • Metalloendopeptidases / antagonists & inhibitors
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / prevention & control
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Peptide Fragments / antagonists & inhibitors
  • Plasminogen / antagonists & inhibitors
  • Platelet Factor 4 / antagonists & inhibitors
  • Sesquiterpenes / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Cyclohexanes
  • Endothelial Growth Factors
  • Integrins
  • Lymphokines
  • Peptide Fragments
  • Sesquiterpenes
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Platelet Factor 4
  • Angiostatins
  • Plasminogen
  • Metalloendopeptidases
  • O-(Chloroacetylcarbamoyl)fumagillol